Chemoimmunotherapy

Chemoimmunotherapy is chemotherapy combined with immunotherapy. Chemotherapy uses different drugs to kill or slow the growth of cancer cells; immunotherapy uses treatments to stimulate or restore the ability of the immune system to fight cancer.[1] A common chemoimmunotherapy regimen is CHOP combined with rituximab (CHOP-R) for B-cell non-Hodgkin lymphomas.

Cancer treatment has progressed to combine different methods to improve the chances of survival. Surgery and radiation therapy are used to control cancer in specific areas, while systemic therapies (such as chemotherapy, endocrine therapy, targeted therapies, and bisphosphonates) are used to manage widespread cancer or cancer that has spread from its original site.[2] Combining different therapies, including multiple drugs with complementary effects, has become common. This approach has been shown to improve five-year survival rates and delay the return of tumors.

  1. ^ "Definition of chemoimmunotherapy". NCI Dictionary of Cancer Terms. U.S. National Institutes of Health. One or more of the preceding sentences incorporates text from these sources, which are in the public domain: National Cancer Institute
  2. ^ Emens LA (2010). "Chemoimmunotherapy". Cancer Journal. 16 (4): 295–303. doi:10.1097/PPO.0b013e3181eb5066. PMC 2919833. PMID 20693839.